Brief: Akari Therapeutics PLC Enters Ordinary Share Purchase Agreement With White Lion Capital
29/08/2025 22:09
Aug 29 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS PLC - ENTERS ORDINARY SHARE PURCHASE AGREEMENT WITH WHITE LION CAPITAL - SEC FILING AKARI THERAPEUTICS PLC - CAN SELL UP TO $25 MILLION OF SHARES - SEC FILING Further company coverage: AKTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics